Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6 Sarcoma 3 Thyroid Cancer, Papillary 2 Salivary Gland Neoplasms 2 Brain Neoplasms 2 Wilms Tumor 1 Solid Tumors 1 Solid Tumor 1 Sarcoma, Ewing 1 Recurrence 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Nephroma, Mesoblastic 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Medulloblastoma 1 Lymphoma, Large-Cell, Anaplastic 1 Locally Advanced Solid Tumors 1 Head and Neck Neoplasms 1 Glioma 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Cancers With NTRK, ROS1, or ALK Gene Fusions 1 Breast Neoplasms 1

Interventions

pembrolizumab 133 Gemcitabine 101 Paclitaxel 100 Carboplatin 84 Nivolumab 66 Docetaxel 62 Bevacizumab 62 Cisplatin 57 Pemetrexed 50 Fluorouracil 49 Cyclophosphamide 41 Cetuximab 41 trametinib 38 venetoclax 37 Leucovorin 37 Irinotecan 37 Sorafenib 35 Capecitabine 35 Ipilimumab 33 Dexamethasone 32 atezolizumab 31 Erlotinib Hydrochloride 28 130-nm albumin-bound paclitaxel 28 Drug Therapy 27 Epoetin Alfa 26 Doxorubicin 25 Oxaliplatin 24 Albumin-Bound Paclitaxel 24 Prednisone 23 Rituximab 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Neoplasms × entrectinib × Clear all

NCT05862285 2026-05-12

UmbrellaMAX

Hoffmann-La Roche

Phase 3 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡